Skip to navigation

Head and Neck Squamous Cell Carcinoma
(Head and Neck Cancer)

Indications: Head and Neck Squamous Cell Carcinoma
Drug Candidate: MGCD265
Driver Mutations: MET, Axl

Mirati Therapeutics is enrolling a Phase 1 study evaluating the effects of MGCD265 as a treatment for head and neck cancer whose tumors carry genetic alterations of MET and Axl. Participating trial sites will analyze the molecular profile of the tumors of eligible patients to determine if those mutations are present before enrolling in the clinical trial.

Find an Active Trial

Other Trials